Stifel pulls a $1.35 billion team from Raymond James, while LPL draws from Edward Jones and Wells Fargo, in advisor moves ...

Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on RegenXBio (RGNX – Research Report) today and set a price target of $40.00.

The largest arbitration award granted to retail clients is the third ruling against Stifel involving advisor Chuck Roberts. More cases are in the pipeline.